The guideline also makes recommendations on dementia diagnosis, based on a review of the latest evidence.
This guideline is an update of the NICE guideline on dementia (CG42, published November 2006) and replaces it. It also replaces recommendation 1.3 in the NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (TA217).
NICE has also produced a guideline on mid-life approaches to delay or prevent the onset of dementia.